3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
5
OTHER_GOV
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
apatinib
25
Cisplatin
19
Capecitabine
17
Irinotecan
16
Cyclophosphamide
16
fludarabine
14
Radiotherapy
12
Oxaliplatin
12
Drug Therapy
12
camrelizumab
11
Paclitaxel
11
S 1 (combination)
10
Docetaxel
10
Carboplatin
10
Fluorouracil
9
Blood Specimen Collection
9
Bevacizumab
9
Nivolumab
8
tislelizumab
7
Radiation
7
Pemetrexed
7
Gemcitabine
7
Erlotinib Hydrochloride
7
Surgical Procedures, Operative
6
Neoadjuvant Therapy
6
Albumin-Bound Paclitaxel
6
toripalimab
5
anlotinib
5
XELOX
5
Tamoxifen
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
OTHER_GOV
×
peginterferon alfa-2a
×
Clear all
NCT02381379
2020-09-14
MSIT
Ministry of Health, Malaysia
Phase 3
Unknown
118 enrolled